Abstract B2: Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abstract B2: Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer.

Published:2013-11 Issue: Volume: Page:
ISSN:
Container-title:Angiogenesis and Antiangiogenesis Agents
language:
Short-container-title:

Author:

Chiron Marielle,Bagley Rebecca G.,Pollard Jack,Henry Christophe,Mankoo Parminder,Vincent Loic,Geslin Catherine,Kloss Tatjana,Bergstrom Donald A.

Publisher

American Association for Cancer Research

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G;Targeted Oncology;2024-03

2. ASSET;European Journal of Psychological Assessment;2021-01

3. Employment impact on hospitality and tourism students’ academic journey: the HBCU students’ perspective;Journal of Teaching in Travel & Tourism;2020-01-05

4. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases;Oncology Letters;2016-08-30

5. Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC);Targeted Oncology;2016-07-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP